A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1/2
33
about 2.1 years
18+
Male only
10 sites in CO, CT, FL +6
About this study
This trial is testing a treatment called HLD-0915 for men with advanced prostate cancer that has not responded to other treatments. The goal is to see if this treatment is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take HLD-0915
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Phase 1: Frequency and severity of AEs and serious adverse events (SAEs), including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs changed from baseline
Secondary: Phase 1: Duration of response (DOR), Phase 1: Objective response rate (ORR) per RECIST in evaluable patients, Phase 1: Plasma PK Parameters (AUC0-inf), Phase 1: Plasma PK Parameters (Cmax), Phase 1: Plasma PK Parameters (T1/2), Phase 1: Plasma PK Parameters (Tmax), Phase 1: Radiographic progression-free survival (rPFS)
Oncology